Global Solutions for Infectious Diseases

“PRIOR TO FILING, A COMPLETE COPY OF THE FINAL FORM 990 WAS DISTRIBUTED TO ALL VOTING BOARD MEMBERS WHO REVIEWED AND DISCUSSED THE RETURN. THE DISCUSSION WAS FORMALIZED IN THE BOARD MINUTES AND A RESOLUTION WAS PROPOSED AND VOTED UPON TO DOCUMENT THE REVIEW AND GIVE AUTHORIZATION TO THE DEPUTY EXECUTIVE DIRECTOR TO FILE THE RETURN WITH THE INTERNAL REVENUE SERVICE. Part VI, Section B, line 12c The Board is charged with monitoring proposed or ongoing transactions for conflicts of interest and addressing any potential or actual conflicts. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire, aimed at determining any family and business relationships and transactions or other transactions that may pose a potential conflict, is distributed to all covered persons (i.e., board members, officers and executive leadership or key employees). Covered persons are required to disclose real or potential conflicts at the time when such conflicts arise. When someone becomes a covered person and annually thereafter, each covered person is required to sign a statement affirming that he/she: (1) has received a copy of the Conflict of Interest Policy; (2) has read the Policy and understands said Policy; and (3) agrees to comply with all requirements of the Policy, including completing the conflict of interest questionnaire. The completed questionnaires are reviewed by the Board and any persons with actual or potential conflicts are informed via written communication. The procedures for addressing any conflict of interest includes, but is not limited to, the following: (1) the conflicting interest is fully disclosed to the Board; (2) the interested person responds to factual questions related to the substance of the transaction or arrangement being considered, after which he/she shall leave the meeting; (3) the person with the conflict of interest is excluded from the discussion and approval of such transaction; (4) alternatives to the proposed transaction are investigated, competitive bids or comparable valuations are obtained; and (5) the transaction or action must be approved by a majority of disinterested persons. Part VI Section B Line 13 GSID is a scientifically-based organization which encourages open communication and the exchange of ideas and opinions. Because it is a small organization, it does not believe it is necessary to implement a formal whistleblower policy.”

“COMPENSATION POLICY Compensation of the organization's two officers is decided upon and approved by the board of directors. The board utilizes industry data to determine salary levels and increases. Because the organization's two internal directors are also active officers, the director cannot approve his salary and therefore must recuse himself from the board action. The external board member is always included in the compensation approval process.”

“Dissemination of Financial Information GSID makes its financial information available upon request and on websites such as Guidestar.”

“Description:neutralization assys - mbi total fees:23565”

“Description:protein characterization - kbi total fees:26834”

“Description:biostatistician total fees:12638”

“Description:consultant's fees total fees:66632”

“Description:consultant's expenses total fees:1183”

“Description:stability testing - crl total fees:135181”

“Description:benefits administration total fees:3556”

“Description:software development total fees:21656”